Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

New Changes in SAC Capital’s 13F Portfolio: Annies Inc (BNNY), Cytokinetics, Inc. (CYTK) And Other

In another round of filings with the Securities and Exchange Commission, Steven Cohen and his fund, SAC Capital Advisors, have disclosed 4 new moves: reductions in the ownership of Annies Inc (NYSE:BNNY) and American Woodmark Corporation (NASDAQ:AMWD), an increase in the holding of Silicon Motion Technology Corp. (ADR) (NASDAQ:SIMO) and a new position – Cytokinetics, Inc. (NASDAQ:CYTK).

Steven Cohen

Cohen has reduced his fund’s stake in Annies Inc (NYSE:BNNY) to 890,400 shares or 5.2% of the total number of shares outstanding. Ken Griffin, on the other hand, is bullish on this stock, having increased his fund’s stake by 900% in the Q4 of 2013. The company engages in the production and distribution of natural and organic food products. It has a market cap of $647 million and does not pay a dividend. The stock is traded at a Price to Earnings (P/E) ratio of 45.xx, almost three times the industry average of 15.40. The stock has been in a downtrend since October 2013 and has depreciated by approximately 12% so far this year to a current price of $37.94 per share.

Another reduction, albeit a small one, is American Woodmark Corporation (NASDAQ:AMWD). SAC has slightly reduced its position to 1.04 million shares, which account for 6.7% of the company’s common stock. Chuck Royce, the manager of Royce & Associates, also slightly reduced his fund stake to approximately 594,400 shares valued at $23.5 million. The company has recently announced its financial performance for the three months ending January 31, 2014: $169 million in revenues and earnings of $0.18 per share. Analysts expect the company to post revenues of $187 million and earnings per share (EPS) of $0.4 for the current quarter.

Silicon Motion Technology Corp. (ADR) (NASDAQ:SIMO) ended up on the Cohen’s buy list, with SAC Capital reporting an increase by almost 500,000 shares of its position, taking it to 1.69 million shares or 5.2% of the company’s common stock. D. E. Shaw is also bullish and has increased his fund’s stake by 39% during the last quarter of 2013. The company has a market cap of $553 million and pays an annual dividend of $0.6, yielding 3.5%. The stock is traded at a trailing P/E ratio of 21.xx, which is pretty much inline with the industry average of 20.00. For the three months ending December 31, 2013, Silicon Motion Technology posted revenues of $52.5 million and EPS of $0.16.

Steven Cohen has recently started a new position in Cytokinetics, Inc. (NASDAQ:CYTK). Together with SAC Capital, Cohen holds a little over 2 million shares, which account for 5.5% of the total number of shares outstanding. Jim Simmons seems to share Cohen’s outlook for this company, having himself initiated a new position. This biopharmaceutical company has a market cap of $344 million and does not pay a dividend. So far this year, the stock has advanced 47% to a current price of $9.55 per share. Cytokinetics announced revenues of $24.3 million and earnings of $0.22 per share for the 2013 fourth quarter. 2014 first quarter is expected to bring revenues of $7.69 million and a loss per share of $0.35.

Disclosure: none.

Recommended reading:

SAC Capital’s Latest Portfolio Moves: Zynga Inc (ZNGA), Tessera Technologies, Inc. (TSRA) And Others

Second Wave of Moves from SAC Capital

Recent Changes in SAC Capital Advisors’ Equity Portfolio

Loading Comments...